About Virscio | Enabling Next Generation Therapeutic Development

Who We Are

We support the development of your diseases interventions and biomedical innovations. From our commitment to knowing and improving the human condition comes our name: Virscio (to know “scio” humans “vir”).

As a specialized AAALAC accredited, GLP-compliant preclinical contract research organization, Virscio engages with leading academic institutions, venture and private equity-backed biotechnology companies, and global pharmaceutical companies to help design and execute capital efficient science that is focused on de-risking the elements of drug development that commonly contribute to failed clinical trials.

Pursuing a science-first focus, we leverage three decades of preclinical experience and deep nonhuman primate datasets to inform thoughtful, value-add preclinical study designs that yield definitive, actionable outcomes to inform program decision making.

What We Do

We address translational risks by applying best understanding of human pathophysiology to inform the execution of non-GLP and GLP studies designed to evaluate delivery, pharmacokinetics, pharmacodynamics, safety, and efficacy of candidate therapeutics.

As stewards of a globally unique nonhuman primate resource, we maintain the very highest ethical and scientific standards to drive the best possible study designs, data analysis, and animal care and use. We embrace these responsibilities and are recognized internationally for this commitment.

Differentiating Expertise, Capabilities, and Resources

Virscio represents a multi-decade dedication to achieving more efficient biomedical innovation, while elevating animal welfare and lowering the overall cost to successfully advance a therapeutic from concept to clinic.

Fully integrated in vivo, histopathology, and molecular research cores, enabling seamless scientific engagement and research service delivery

PhD and MD Subject Matter Experts (SMEs) leading engagement, scientific strategy and protocol development to ensure study execution is aligned to development objectives

Humane, sustainable access to a large, biologically clean nonhuman primate population, comprised of island (F0) and breeding-colony sourced (F1, F2) animals.
Dedicated IACUC, enabling thorough and time efficient review and approvals - often within 14 days or less
Deep scientific and clinical expertise in CNS, ophthalmology, cardiovascular, and metabolism
Extensive library of validated histomolecular assays to support both primate and non-primate tissue analyses
Expedited initiation timelines, with flexible study protocol and contract amendment process
Robust data analysis and study reporting, and commitment to generating definitive, actionable study outcomes and conclusions

CRO that has the ability to provide new and novel model development services in addition to basic standard nonhuman primate work.

I believe from a disease model perspective [they have] a unique niche. There are NO peers/competitors for reliable primate models for key diseases such as neurologic/ophthalmic.

Easy to work with and access to African green monkeys, a perfect model to do ophthalmology studies. Lead time to getting a project started is significantly reduced because they are onsite and easily available.

Not your typical recipe book CRO.

Premiere translational CRO.

The Council commends you and staff for providing and maintaining and exemplary program of laboratory animal care and use. - AAALAC International

Matthew Lawrence, M.D., Ph.D.

Chief Executive Officer, Chief Scientific Officer

Virscio Co-founder, Matthew Lawrence is responsible for overseeing design and execution of Virscio’s preclinical studies and alignment of research capabilities to achieve sponsor development objectives. Dr. Lawrence has over 35 years of experience in nonhuman primate research and over 20 years designing, executing and leading NIH and industry-funded R&D programs that leverage Virscio’s translational platform to de-risk therapeutic targets and candidates. Dr. Lawrence has been instrumental in the design and execution of preclinical programs for a wide range of academic groups, venture-backed start-ups, and publicly traded biotechnology and pharmaceutical companies. Dr. Lawrence received a BA in Biology and Geology from Harvard College, PhD in Neuroscience from Stanford University as a Howard Hughes Medical Institute Predoctoral Fellow, and MD from Yale School of Medicine. Dr. Lawrence completed his internship in medicine at the University of Hawaii and ophthalmology residency at Massachusetts Eye and Ear Infirmary.

Matthew Lawrence, Ph.D. - Chief Executive Officer, CSO, Co-founder

Christopher Stanley

Chief Business Officer, Chief Financial Officer

Virscio Co-founder, Christopher is a life sciences executive and entrepreneur with over 25 years of experience in financing, building, operating and supporting companies developing and commercializing biomedical research innovations. Mr. Stanley oversees corporate strategy, business development, financing and investing activities associated with the development and commercialization of Virscio’s translational R&D platform. Under Mr. Stanley’s leadership, Virscio has designed and executed an integrated commercial, partnering, and financial plan that that has enabled significant, sustainable growth. Prior to co-founding Virscio, Mr. Stanley held positions at Accenture within the Corporate Transaction Services group where he focused on evaluating and structuring complex outsourcing, joint-venture, and equity investment transactions. Prior to Accenture, Mr. Stanley was an Analyst in the Global Markets Group at JPMorgan Chase. Mr. Stanley received his BBA in Finance from the University of Texas at Austin.